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Abstract
Objective: Hemorrhagic cystitis (HC) is a generally self-limited complication of hematopoietic stem cell transplantation 
(HSCT). It may occur in the early or late posttransplant period and can promote sometimes severe morbidity. We analy-
zed our data regarding HC in allogeneic HSCT patients in order to establish the efficacy of hyperbaric oxygen (HBO) the-
rapy in severe HC and to document the main problems during its use. 
Material and Methods: Between March 1993 and August 2006, 161 patients received allogeneic HSCT. Mesna, 
hyperhydration and forced diuresis were used as early HC prophylaxis of cyclophosphamide-induced HC. However, 
HC was diagnosed in 49 of the 161 recipients and 17 of them were considered as severe HC. We analyzed their data 
retrospectively.
Results: Forced diuresis with hyperhydration (up to 8 L/day) and transfusion support to maintain a platelet count 
above 30x109/L were sufficient in 10 of the 17 patients with severe HC. Alternative therapies used included intravesi-
cal irrigation with formalin and prostaglandin (PG)F2 alpha and HBO, and HBO appeared to be the most useful among 
them. 
Conclusion: We conclude that HBO offers a noninvasive therapeutic alternative in the management of intractable HC in 
the HSCT setting. (Turk J Hematol 2009; 26: 176-80)
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Özet
Amaç: Hemorajik sistit, hematopoetik kök hücre naklinin genellikle kendiliğinden düzelen bir yan etkisidir. Nakil sonrası 
erken ve geç dönemlerde gelişebilen bu komplikasyon bazen oldukça ağır geçebilmektedir. Biz allojeneik hematopoetik 
kök hücre nakli sonrası hemorajik sistit gelişen olgularımızı, özellikle hiperbarik oksijen tedavisinin bu olgulardaki etkinliğini 
ve kullanımda dikkat edilmesi gereken özellikler açısından değerlendirdik. Introduction
Hemorrhagic cystitis (HC) is a frequent complication of 
hematopoietic stem cell transplantation (HSCT). The reported 
frequency changes mainly with the definition (according to 
inclusion or exclusion of microscopic hematuria) and preventive 
manipulations. It may occur in the early or late posttransplant 
period and can promote sometimes severe morbidity. Several 
risk factors are reported to date, which include drugs, chemical 
toxins, infection, and pelvic irradiation [1,2]. It is mostly self-
limited, and supportive treatment with hyperhydration and 
increased transfusion can be sufficient [3]. To facilitate the 
urinary flow, placement of urinary catheter is sometimes 
needed for intermittent or continuous bladder irrigation. 
Instillation of agents such as alum, silver nitrate, prostaglandin 
(PG) or formalin is the therapeutic intervention used to halt 
hemorrhage in severe HC [4-7]. 
Such agents are cumbersome for both patients and 
physicians and are seldom selected. Hyperbaric oxygen (HBO) 
therapy is a relatively new treatment modality for HC. The role 
of HBO therapy in HC was reported firstly in radiation-induced 
cystitis, but in recent years HBO has also been used in 
cyclophosphamide (CY)-induced HC [8-13]. It decreases 
tissue edema and ensures the necessary oxygen gradients 
required to stimulate continued angiogenesis, fibroblast 
proliferation, collagen formation, and leukocyte activation, 
which are required for tissue healing and repair [9]. We 
analyzed our data regarding HC in allogeneic (allo)HSCT 
patients in order to establish the efficacy of HBO therapy in 
severe HC and to document the main problems occurring 
during its use. 
Materials and Methods
Between March 1993 and August 2006, 161 patients 
underwent alloHSCT (bone marrow transplantation (BMT): 
n=91; peripheral blood (PB) stem cell transplantation: n=70). 
All of the patients had hematological malignancies except three 
(aplastic anemia: n=2; paroxysmal nocturnal hemoglobinuria: 
n=1). The donors were all HLA-matched siblings. One hundred 
fifty-three of the patients received CY (60 mg/kg per day-2) as 
part of the conditioning regimen combined with busulfan (in 
136 patients) (4 mg/kg per day divided in 4 doses-4) or total 
body irradiation (TBI) (in 17 patients) (1200 cGy). Mesna (6 
mercapto-ethane sodium sulphonate, a sulfhydryl-containing 
compound) (1/2 of the CY total dose x 6), hyperhydration (3 L/
m2/day) and forced diuresis were used as early HC prophylaxis 
of CY-induced HC. The first dose of Mesna was given 30 
minutes before CY infusion, and was followed by subsequent 
infusions every four hours until the day following the last dose 
of CY. Cyclosporine (CsA, 12.5 mg/kg per day divided in 2 
doses) and a short-course of methotrexate (15 mg/m2 per day 
on day-1 and 10 mg/m2 per day on days-3,-6 and-11) were 
given as graft-versus-host disease (GVHD) prophylaxis. Written 
informed consent was obtained from all patients.
Heme dipstick testing was used as a method for hematuria 
investigation and was performed on a daily basis beginning 
with conditioning regimen until the end of hospitalization. When 
heme was found to be positive, the urine specimen was sent 
for microscopic analysis and culture. Diagnosis of HC was 
based on the appearance of microscopic hematuria with 
negative bacterial and fungal culture. HC was graded according 
to the following criteria: grade I, microscopic hematuria; grade 
II, macroscopic hematuria without clots; grade III, macroscopic 
hematuria with clots; and grade IV, gross hematuria and clinical 
complications secondary to urinary outflow obstruction. 
Patients with grade III and grade IV were accepted as having 
severe HC. Urine culture for adenovirus could be performed in 
only five patients. Cytomegalovirus (CMV) antigen was screened 
in both PB and urine samples in all the patients with HC. We 
did not have the opportunity to screen the urine for BK virus in 
our patients with HC.
When severe HC is diagnosed in our HSCT unit, forced 
diuresis with hyperhydration (3 L/m2 up to 8 L/day) and 
transfusion support to maintain a platelet count above 30x109/L 
are the first-line treatment methods employed. Pelvic 
ultrasonographic examination is also performed in those 
patients to determine any obstruction in the vesicle and, if 
present, continuous bladder irrigation at 6-7 L/day through a 
tri-lumen irrigation catheter is also started. If severe HC is 
refractory to the first-line management, we choose alternative 
therapies such as intravesical instillation of PG (200 micrograms 
in 50cc isotonic sodium chloride solution), formalin and/or 
HBO therapy. We could not perform alum irrigation in our 
patients.
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Yöntem ve Gereçler: Mart 1993 ve Ağustos 2006 yılları arasında 161 hastaya allojeneik hematopoetik kök hücre nakli 
uygulandı. Siklofosfamide bağlı hemorajik sistit gelişimi engelleyebilmek amacıyla profilaktik olarak Mesna, hiperhidrasyon 
ve zorlu diürez uygulandı. Buna rağmen 161 olgunun 17’si ağır olmak üzere 49’unda hemorajik sistit gelişti. Tedavi yakla-
şımı ve bulgular geriye dönük olarak değerlendirildi. 
Bulgular: Zorlu diürez ve günde 8 litreye varan hiperhidrasyon tedavisi ile trombosit sayısını 30.000/mm3 üzerinde tuta-
cak şekilde trombosit transfüzyonları ağır hemorajik sistit olan olguların 10’unda yeterli oldu. Alternatif tedavi yaklaşımları 
olarak mesane içinin formalin ve prostaglandin F2 alpha ile yıkanması ile hiperbarik oksijen tedavisi kullanıldı. Bu tedaviler-
den en yararlısının hiperbarik oksijen olduğu gözlendi. 
Sonuç: Bu nedenle özellikle hematopoetik kök hücre nakilleri sonrası gelişen inatçı hemorajik sistit olgularının tedavisinde 
hiperbarik oksijen uygulamasının önemli bir tedavi yaklaşımı olduğunu düşünüyoruz. (Turk J Hematol 2009; 2009; 26: 176-80) 
Anahtar kelimeler: Hiperbarik oksijen, hemorajik sistit, kök hücre nakli
Geliş tarihi: 17 Mart 2009  Kabul tarihi: 1 Eylül 2009HBO therapy: Patients were referred to the HBO center. All 
patients received HBO therapy in a single room. They received 
100% oxygen at 2.5 atmospheres chamber pressure for 120 
minutes daily at least one month but continued until the 
symptoms subsided and bleeding completely disappeared. All 
calculations were performed using the SPSS software package, 
version 14 (SPSS Inc, Chicago, IL, USA)
Results
Hemorrhagic cystitis was diagnosed in 49 of 161 (30%) 
HSCT recipients at a median +39 days (range: from -2 to +241 
days). HC occurred in 25 of the 70 alloPBSCT group (36%) 
and in 24 of the 91 BMT group (26%), and the difference was 
not statistically significant (p=0.228).
Seventeen of the 49 HC cases (8 BMT, 9 PBSCT) were 
described as severe HC (>grade II). Although most of our 
patients with HC responded to the first-line therapies, HC 
affected the morbidity in a median of 12 days (range: 4- 90 
days). Nine of the patients died before resolution of HC with 
complications of severe GVHD. 
Four of the HC cases (8.1%) developed in the first week of 
the transplantation and preparative regimens in these cases 
included CY and busulfan. Urine culture for adenovirus was 
found to be positive in one case. CMV antigenemia was also 
observed in six of the patients with HC. 
The results of all patients with HC: Forced diuresis with 
hyperhydration up to 8 L/day and transfusion support to 
maintain a platelet count above 30x109/L were sufficient in all 
the patients with mild HC and in eight of the 17 patients with 
severe HC. Cystoscopy was needed in 14 of the patients and 
evacuations of the hematoma were performed before increasing 
the irrigation solutions up to 30-40 L/day. Vesical sarcoma was 
diagnosed in one case with cystoscopy and the patient 
underwent radical cystectomy. Alternative therapies were 
applied in eight of the patients. The first patient was successfully 
treated with intravesical formalin irrigation therapy. The next 
patient did not respond to formalin and then intravesical PGF2 
alpha irrigation and was successfully treated with HBO 2.4 
atmospheres absolute (30 minutes 3 times daily for 8 days). 
The results of HBO therapy: We performed HBO as a first-
choice alternative therapy in another six patients. All results for 
these seven cases are summarized in Table 1. We found HBO 
therapy quite useful in our first four cases. We followed our 
patients with weekly CMV antigenemia and noted CMV 
reactivation in our fifth patient after three days of HBO and 
stopped the therapy. This patient died with multiorgan failure 
after three months follow-up and HC never resolved. We only 
used three and four days of HBO therapy, respectively, in our 
last two patients and they also died with severe GVHD and 
severe HC in a short period of two weeks. 
Discussion
Hemorrhagic cystitis can occur at any time after HSCT and 
may affect the morbidity of the procedure. The incidence of HC 
varies considerably according to the preparative regimen, the 
preventative measures employed and perhaps the incidence of 
GVHD. HC occurring during or shortly after the conditioning 
regimen of high-dose chemotherapy or chemoradiotherapy is 
referred to as early-onset [14]. Oxazaphosphorine drugs such 
as CY or ifosfamide have been widely used as preparative 
regimen agents. The acrolein formed as a urinary byproduct of 
the metabolism of these drugs is thought to be responsible for 
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Table 1. Clinical findings and therapy results of 7 patients with intractable hemorrhagic cystitis (HC)
  Case 1  Case 2  Case 3  Case 4  Case 5  Case 6  Case 7
Age, sex   42, Male  32, Female  22, Male  20, Female  26, Male  23, Female  21, Female
Disease CML  CML  CML  CML  T-ALL  B-ALL  CML
Stem cell source  PBSC  PBSC  BMT  PBSC  BM  BM  BM
Preparative regimen  Bu/CY  Bu/CY  Bu/CY  Bu/CY  Bu/CY  Bu/CY  Bu/CY
GVHD grade    2  -  -  2  2  2
HC grade and time  III, day +69  II, day +32  III, day +27   III, day +60  IV, day +45  IV, day +60  IV, day +32
Alternative therapies  Intravesical  -  -  -  -   -
 formalin,  PGF2 
Duration  3 weeks  21 days   5 weeks  21 days  3 months  ?  ?
HBO response  in 8 days  in 10 days  in 14 days  in 9 days  -   -
(Until asymptomatic) 
HBO duration  35 days  40 days  60 days  40 days  3 days  3 days  4 days
HBO complication  none  none  none  none  CMV reactivation??  none  none
Last visit  Exitus  Alive  Alive  Alive  Exitus  Exitus  Exitus
CML: Chronic Myelogenous Leukemia  ALL: Acute Lymphoblastic Leukemia  PBSC: Peripheral Blood Stem Cell  BM: Bone Marrow the urothelial toxicity [1]. We use Mesna and hyperhydration 
protocol for the prevention of CY-induced HC in our Unit. In our 
study, since only four out of 49 HC cases (8.1%) developed in 
the first week of the transplantation, we consider this to be 
quite effective in preventing early-onset HC. Preparative 
regimens of these cases were also composed of busulfan, 
which may have been an additional risk factor for early HC in 
these patients [15]. We observed an incidence of HC of 30% 
in our study, which is comparable with the other reports (1,16). 
We analyzed our patients to see if stem cell source had any 
effect on this complication, but were unable to determine any 
statistically significant difference with respect to incidence or 
severity of the HC (p=0.228 and p=0.445, respectively).
Hemorrhagic cystitis cases occurring weeks to months 
after HSCT are referred to as late-onset HC. Early HC is one of 
the recognized risk factors for late HC, but significant 
proportions of the late HC cases are reported to be associated 
with viruria and/or GVHD. The viruses most frequently 
implicated in HC are BK polyomavirus and adenovirus type 11 
[16-18]. HC is generally self-limited and usually resolves in a 
few days to weeks without any sequelae. Occasionally, 
intermittent or persistent hematuria may be severe enough to 
require frequent transfusions. In more severe cases, cystoscopy 
should be performed to determine any problems with the 
vesical mucosa and to remove blood clots, followed by 
continuous bladder irrigation [19]. We diagnosed vesical 
sarcoma in one of our patients who required cystoscopy. Eight 
of the severe HC cases in our study failed to respond to 
standard management. Formalin and PGF2a were chosen for 
intravesical instillation in addition to bladder irrigation and 
platelet transfusions in two patients, respectively. Formalin was 
effective in controlling bleeding but PGF2 was not, which was 
likely due to insufficient doses because of the limited supply of 
this drug in our country [20]. Our first patient became 
asymptomatic in eight days with HBO therapy. We used this 
treatment modality in all seven cases with intractable HC. We 
used HBO therapy without any other alternative therapies in 
our other three responding patients, who became asymptomatic 
in 10, 14 and 9 days of HBO, respectively. We used HBO until 
microscopic hematuria disappeared in those patients. We 
followed our patients with weekly CMV antigenemia and 
determined CMV reactivation in our fifth patient after three days 
of HBO therapy. Although it might have been a coincidental 
finding in such a patient with severe GVHD, we thought HBO 
therapy might have facilitated the reactivation of GVHD and 
stopped the therapy despite persistent HC in that patient. We 
were unable to use HBO effectively in our last two patients 
because of severe CMV infection and graft failure symptoms 
and death was anticipated. We did not want to accept these 
cases as HBO- unresponsive because of the very short 
duration of the therapy. 
Clinical and experimental studies suggest that HBO could 
be useful in preventing chemotherapy-induced HC [21-23]. 
HBO is considered as an adjunctive treatment to medical and 
surgical care. HBO induces the healing of tissue damage, 
decreases edema and promotes capillary angiogenesis by 
increasing tissue oxygen levels. Plafki et al. [24] reviewed 
complications and side effects in 782 patients treated for 
various indications, with a total of 11,376 HBO therapy 
sessions, and summarized that the predominant complication 
is related with pressure equalization problems within the 
middle ear. We did not observe any complication directly 
related with HBO therapy. We did observe CMV reactivation 
coincidentally during HBO therapy, and even though we could 
not determine any deleterious effect such as viral reactivation, 
we stopped the therapy. There are some reports speculating 
that HBO therapy has an antiviral effect in hepatitis B and 
human immunodeficiency virus infection [25,26]. We conclude 
that moder ately severe HC can be treated conservatively in 
most patients. When hyperhydration, transfusion support and 
intravesical irrigation fail to treat HC, addition of HBO therapy 
may be beneficial, and HBO treatment should be considered 
without further delay.
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